Purple Biotech Ltd. Updates Company Presentation
Ticker: PPBT · Form: 6-K · Filed: Oct 9, 2024 · CIK: 1614744
Sentiment: neutral
Topics: company-update, investor-relations
TL;DR
Purple Biotech dropped a new investor deck on their site, check Exhibit 99.1.
AI Summary
On October 9, 2024, Purple Biotech Ltd. announced it has made an updated Company Presentation available on its website. This presentation is attached as Exhibit 99.1 to the filing.
Why It Matters
Investors and interested parties can access the latest information and strategic overview of Purple Biotech Ltd. directly from the company's updated presentation.
Risk Assessment
Risk Level: low — This filing is an informational update regarding a company presentation and does not involve significant financial transactions or operational changes.
Key Players & Entities
- Purple Biotech Ltd. (company) — Registrant
- October 9, 2024 (date) — Announcement Date
- Exhibit 99.1 (document) — Attached Presentation
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose is to announce that Purple Biotech Ltd. has made an updated Company Presentation available on its website.
When was the updated Company Presentation made available?
The updated Company Presentation was made available on October 9, 2024.
Where can the updated Company Presentation be found?
The updated Company Presentation is available on Purple Biotech Ltd.'s website and is attached to the filing as Exhibit 99.1.
What is the Commission File Number for Purple Biotech Ltd.?
The Commission File Number for Purple Biotech Ltd. is 001-37643.
What is the principal executive office address for Purple Biotech Ltd.?
The principal executive office address is 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel.
Filing Stats: 571 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2024-10-09 07:41:00
Filing Documents
- ea0217152-6k_purple.htm (6-K) — 14KB
- ea021715201ex99-1_purple.htm (EX-99.1) — 80KB
- ex99-1_001.jpg (GRAPHIC) — 181KB
- ex99-1_002.jpg (GRAPHIC) — 340KB
- ex99-1_003.jpg (GRAPHIC) — 139KB
- ex99-1_004.jpg (GRAPHIC) — 151KB
- ex99-1_005.jpg (GRAPHIC) — 166KB
- ex99-1_006.jpg (GRAPHIC) — 175KB
- ex99-1_007.jpg (GRAPHIC) — 279KB
- ex99-1_008.jpg (GRAPHIC) — 281KB
- ex99-1_009.jpg (GRAPHIC) — 179KB
- ex99-1_010.jpg (GRAPHIC) — 300KB
- ex99-1_011.jpg (GRAPHIC) — 204KB
- ex99-1_012.jpg (GRAPHIC) — 204KB
- ex99-1_013.jpg (GRAPHIC) — 236KB
- ex99-1_014.jpg (GRAPHIC) — 194KB
- ex99-1_015.jpg (GRAPHIC) — 161KB
- ex99-1_016.jpg (GRAPHIC) — 258KB
- ex99-1_017.jpg (GRAPHIC) — 256KB
- ex99-1_018.jpg (GRAPHIC) — 169KB
- ex99-1_019.jpg (GRAPHIC) — 163KB
- ex99-1_020.jpg (GRAPHIC) — 265KB
- ex99-1_021.jpg (GRAPHIC) — 175KB
- ex99-1_022.jpg (GRAPHIC) — 170KB
- ex99-1_023.jpg (GRAPHIC) — 228KB
- ex99-1_024.jpg (GRAPHIC) — 222KB
- ex99-1_025.jpg (GRAPHIC) — 287KB
- ex99-1_026.jpg (GRAPHIC) — 200KB
- ex99-1_027.jpg (GRAPHIC) — 238KB
- ex99-1_028.jpg (GRAPHIC) — 167KB
- ex99-1_029.jpg (GRAPHIC) — 179KB
- ex99-1_030.jpg (GRAPHIC) — 137KB
- ex99-1_031.jpg (GRAPHIC) — 133KB
- ex99-1_032.jpg (GRAPHIC) — 279KB
- ex99-1_033.jpg (GRAPHIC) — 134KB
- ex99-1_034.jpg (GRAPHIC) — 250KB
- ex99-1_035.jpg (GRAPHIC) — 141KB
- ex99-1_036.jpg (GRAPHIC) — 156KB
- ex99-1_037.jpg (GRAPHIC) — 120KB
- ex99-1_038.jpg (GRAPHIC) — 215KB
- ex99-1_039.jpg (GRAPHIC) — 200KB
- ex99-1_040.jpg (GRAPHIC) — 164KB
- ex99-1_041.jpg (GRAPHIC) — 188KB
- ex99-1_042.jpg (GRAPHIC) — 165KB
- ex99-1_043.jpg (GRAPHIC) — 178KB
- ex99-1_044.jpg (GRAPHIC) — 63KB
- ex99-1_045.jpg (GRAPHIC) — 164KB
- ex99-1_046.jpg (GRAPHIC) — 155KB
- ex99-1_047.jpg (GRAPHIC) — 249KB
- ex99-1_048.jpg (GRAPHIC) — 222KB
- ex99-1_049.jpg (GRAPHIC) — 145KB
- ex99-1_050.jpg (GRAPHIC) — 244KB
- ex99-1_051.jpg (GRAPHIC) — 177KB
- ex99-1_052.jpg (GRAPHIC) — 133KB
- ex99-1_053.jpg (GRAPHIC) — 269KB
- ex99-1_054.jpg (GRAPHIC) — 228KB
- 0001213900-24-086395.txt ( ) — 14441KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. October 9, 2024 PURPLE BIOTECH LTD. By: /s/ Lior Fhima Lior Fhima Chief Financial Officer 2